Argenx SE (ARGX) shares plummeted 7.09% during intraday trading on Thursday, marking a significant downturn for the biopharmaceutical company.
The sharp decline followed the company's report of a year-over-year decrease in its fourth-quarter earnings. Despite beating analyst expectations, Argenx's Q4 earnings per share fell to $8.02 from $11.79 in the same period last year.
This earnings decline appears to be the primary driver behind the negative investor sentiment and the substantial sell-off observed during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments